GlassScriptPhysician profile
Abdussami Hadi
NPI 1649413709
$3,260.45
in general payments reported to CMS, 2019-2025
27 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $150 · 2021: $626 · 2022: $203 · 2023: $833 · 2024: $460 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244 · Travel and Lodging: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.05 |
| Travel and Lodging | $520.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $565.99 | 2019-2025 | Belbuca, Xtampza |
| Pacira Pharmaceuticals Incorporated | $528.14 | 2023 | Iovera |
| Medtronic, INC. | $332.87 | 2021 | |
| Abbott Laboratories | $237.01 | 2021-2024 | Proclaim, Axium |
| Indivior INC. | $211.90 | 2019-2025 | Sublocade |
| Mdd US Operations, LLC | $195.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.41 | 2019-2025 | Relistor |
| Arbor Pharmaceuticals, INC. | $105.41 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $86.62 | 2023-2025 | Ztlido |
| Virtus Pharmaceuticals LLC | $82.51 | 2021-2024 | Levorphanol Tartrate |
| Orexo US, INC. | $81.73 | 2019-2025 | Zubsolv |
| Redhill Biopharma INC. | $76.52 | 2020-2021 | |
| Forte Bio-Pharma LLC | $73.98 | 2021-2025 | Prolate, Tanlor, Nalocet |
| Protega Pharmaceutials INC | $73.05 | 2022 | |
| Pfizer INC. | $62.66 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $61.09 | 2019 | |
| Bioventus LLC | $54.72 | 2021-2025 | Supartz Fx Sodium Hyaluronate |
| Nevro Corp. | $53.30 | 2019 | |
| Valinor Pharma, LLC | $43.20 | 2024 | Movantik |
| Neuronetics, INC. | $42.94 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $39.83 | 2025 | Kristalose |
| Braeburn INC. | $33.37 | 2023-2024 | Brixadi |
| Boston Scientific Corporation | $30.05 | 2022 | |
| Abbvie INC. | $22.63 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.51 | 2024 | Horizant |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Sentynl Therapeutics, INC. | $15.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdussami Hadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.